VIVA
维亚生物科技控股集团
VIVA BIOTECH HOLDINGS
股票代號:1873

NEWSLETTER

January–April 2025, Issue 20

Highlights

Ⅰ. Business Progress

- Viva Biotech Announced 2024 Annual Results: Significantly Rebounding in Performance with New Stage ahead, AI Leads to a New Era of Novel Drug R&D
- Viva Biotech Announced 2024 ESG Report: Technology Drives the Green Chemistry Revolution, and Multiple Governance Expands the Boundaries of Sustainability
- Viva Biotech AIDD/CADD Platform Continues to Break Through, DeepSeek On-Premises Deployment Enables Acceleration
- Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection
- Viva Biotech's Contribution to Research on Novel DLK Inhibitor Highlighted on the Cover of the "Journal of Medicinal Chemistry"
- Three-Year from Target-to-PCC Success: Viva Biotech's One-stop Integrated Drug Discovery Platform Accelerates Drug Discovery

Ⅱ. Portfolio Companies' Project Progress

- VivaVision's VVN461 Achieves Primary Endpoint in Phase II Clinical Trial for Non-infectious Anterior Uveitis in China
- TechnoDerma Medicines Completes U.S. Positive Ph2a Proof-of-Concept Trial with Topical TDM-180935 Ointment for Atopic Dermatitis
- Mediar Therapeutics Enters into Global Licensing Agreement with Lilly to Advance First-in-Class WISP1 Antibody for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)
- TJ Biopharma Announces NMPA Acceptance of BLA for Felzartamab
- Genhouse Bio's New Generation PRMT5 Inhibitor GH56 Clinical Trial Application Approved by NMPA

Business Progress

WORLD-LEADING ONE-STOP PLATFORM FOR INNOVATIVE DRUG DISCOVERY DEVELOPMENT AND MANUFACTURING

Viva Biotech Announced 2024 Annual Results: Significantly Rebounding in Performance with New Stage ahead, AI Leads to a New Era of Novel Drug R&D

- On March 27, 2025, Viva Biotech Holdings ("Viva Biotech", "the Group" or "the Company", stock code: 1873.HK) announced that for the Group's revenue during the Reporting Period achieved RMB1,986.7 million, gross profit amounted to RMB687.4 million and net profit recorded RMB222.0 million, a significant turnaround from a net loss of RMB99.8 million in the corresponding period of last year, mainly benefiting from the elimination of relevant financial adjustments due to the full repayment of convertible bonds, and an increase in adjusted non-IFRS net profit to RMB314.6 million from RMB208.8 million in the corresponding period of last year, representing an increase of nearly 50.6% as compared to last year, which was mainly attributable to an increase in operating profit margin driven by the recovery of CRO business growth and the improving operational efficiency in 2H2024, as well as the recognition of investment income from milestone payments received by the Group during the year.
- Looking back on 2024, as global biopharmaceutical investment and financing activities gradually picked up, companies engaged in novel drug development also saw a turnaround in pipeline advancement and R&D investments, leading to revenue rebounds across the CRO industry at a quarterly pace. With respect to the Group's CRO business, leveraging its global leadership in protein structure determination, it continued to enhance its technology platforms and expand its worldwide business development (BD) teams while prioritizing AI-driven empowerment of drug discovery platforms to sustain growth in both the number and scale of new projects through integrated wet-lab and dry-lab approaches. Regarding its CDMO business, the Group was steadily advancing CDMO capacity expansion at Langhua Pharmaceutical to prepare for future commercialization of novel molecules, having largely completed the optimization and restructuring of its chemistry, manufacturing, and controls (CMC) operations. Furthermore, the Group continued to benefit from investment returns and synergistic effects generated by its investment incubation initiatives. Overall, throughout the past year, the Group has consistently provided one-stop integrated services spanning from early-stage structure-based drug research and development to commercial drug production, achieving robust financial performance growth.

Business Progress

WORLD-LEADING ONE-STOP PLATFORM FOR INNOVATIVE DRUG DISCOVERY DEVELOPMENT AND MANUFACTURING

Viva Biotech Announced 2024 ESG Report: Technology Drives the Green Chemistry Revolution, and Multiple Governance Expands the Boundaries of Sustainability

- On April 24, 2025, Viva Biotech Holdings (1873.HK) announced 2024 ESG Report. Dr. Cheney Mao, Chairman and CEO of Viva Biotech Holdings, stated:"The Company has been committed to aligning pursuit of business development with fulfilment of its environmental and social responsibilities, and while proactively propelling business growth, the Group has integrated the ESG philosophy into the whole process of business development. Dedicated to operation with integrity, we have made constant efforts to improve corporate governance standards and optimize our ESG governance structure. Meanwhile, the Company has been pursuing sustainability in each and every process of its production and operation activities, in an endeavor to reduce emission and enhance efficiency, conserve resources and contribute to the establishment of an environmental-friendly society and ecological value chain."
- This is the sixth environmental, social and governance report of the Company since its listing on the Hong Kong Stock Exchange, which demonstrates the achievements made by the Group in the environmental, social and governance aspects during the Reporting Period, as well as how we actively responded to the expectations and concerns of our stakeholders with concrete acts. Looking ahead, the Company will continue to improve business performance, cement our foundation with core competitiveness, bear in mind our corporate social responsibilities along our journey forward and live up to our mission to be innovation-driven, empowered by cutting-edge technology, strive for excellence and benefit patients all around the world, aspiring to realize our vision of becoming a long-term partner of global innovative biotech companies.

Viva Biotech AIDD/CADD Platform Continues to Break Through, DeepSeek On-Premises Deployment Enables Acceleration

- Viva Biotech announced on-premises deployment of DeepSeek-R1 model on February 14th to further power intelligent workflow. In the field of AI, Viva Biotech has a deeper layout. As early as the beginning of the AI wave, the company started to build AIDD/CADD platform, and through continuous iteration and systematic optimization, it gradually built up a full-cycle AI-enabled system from target prediction to candidate compounds optimization to preclinical research, which greatly accelerated the process of drug discovery and development. The company innovatively integrates AI with structure-based drug discovery (SBDD) technology, with a focus on new targets, novel mechanisms of action (MOA) and new modality, creating a unique AI-enabled SBDD one-stop FIC R&D service platform for innovative novel drugs.

Business Progress

WORLD-LEADING ONE-STOP PLATFORM FOR INNOVATIVE DRUG DISCOVERY DEVELOPMENT AND MANUFACTURING

Viva Biotech's Wholly-Owned Subsidiary Langhua Pharmaceutical Successfully Passes U.S. FDA On-Site Inspection

- On March 27, 2025, Viva Biotech Holdings ("Viva Biotech") announced that Zhejiang Langhua Pharmaceutical Co., Ltd. ("Langhua Pharmaceutical"), a wholly-owned subsidiary of Viva Biotech Holdings, underwent a cGMP (Current Good Manufacturing Practices) on-site inspection by the U.S. Food and Drug Administration ("FDA"), and received the EIR (Establishment Inspection Report) from the FDA. This is the fourth time that Langhua Pharmaceutical has undergone and passed the on-site inspection by the FDA, indicating the effective operation of the Company's quality control system. It also enables the Company to offer globally customized research, development, and production services to pharmaceutical enterprises worldwide.

Viva Biotech's Contribution to Research on Novel DLK Inhibitor Highlighted on the Cover of the "Journal of Medicinal Chemistry"

- A research result of a global leading computational drug discovery company and pharmaceutical enterprise, a partner of Viva, has successfully published a research featured on the cover of the "Journal of Medicinal Chemistry". Viva Biotech was fully involved in this project and contributed to the discovery and optimization of the active compound KAI-11101. This research titled "In Silico Enabled Discovery of KAI-11101, a Preclinical DLK Inhibitor for the Treatment of Neurodegenerative Disease and Neuronal Injury" showcases the potential of a new DLK inhibitor KAI-11101 in the treatment of neurodegenerative diseases and neuronal injury, it also reveals the process of discovering and optimizing KAI-11101 through computational screening. Marking a successful drug discovery case driven by FEP (Free Energy Perturbation). Hua Zhou, senior Director of chemistry at Viva Biotech, and Dr. Yuansong Jiang, Director of chemistry at Viva Biotech, and Bioassay team participated in the testing, synthesis and optimization of the candidate compounds, providing key support for the successful development of KAI-11101.

Three-Year from Target-to-PCC Success: Viva Biotech's One-stop Integrated Drug Discovery Platform Accelerates Drug Discovery

- Viva Biotech collaborated with a global biotech company developing novel small molecule inhibitors targeting tumors with specific gene deletions via synthetic lethality. Despite the target's therapeutic potential, early compounds faced challenges including poor chemical structures, cellular adaptation, and unfavorable drug metabolism. To overcome these bottlenecks, our partner collaborated with Viva Biotech, utilizing our expertise and technology platforms to accelerate their project with significant clinical potential.
- By integrating our biology and chemistry expertise, Viva Biotech facilitated rapid progression from screening to co-crystal structure in 6 months, lead compound identification within 1 year, and clinical candidate compound selection in 3 years. This effort enabled our client to develop a FIC, mechanism-based anti-cancer drug to late-stage clinical trials.

Portfolio Companies' Project Progress

VivaVision's VVN461 Achieves Primary Endpoint in Phase II Clinical Trial for Non-infectious Anterior Uveitis in China

- On January 3, 2025, VivaVision Biotech ("VivaVision"), invested and incubated by VBI, a clinical-stage, privately held biotechnology company focused on developing treatments for ocular diseases, announced that VVN461 achieves clinical endpoints in Phase II clinical trial for non-infectious anterior uveitis.
- VVN461 is a first-in-class non-steroidal dual JAK1/TYK2 immunomodulator independently developed by VivaVision. It demonstrated excellent anti-inflammatory effects in this clinical trial. Compared to the positive control prednisolone acetate 1% ophthalmic suspension , both dosage groups achieved statistical non-inferiority for both the both primary and secondary endpoints.

TechnoDerma Medicines Completes U.S. Positive Ph2a Proof-of-Concept Trial with Topical TDM-180935 Ointment for Atopic Dermatitis

- On 6 January 2025, TechnoDerma Medicines, Inc. ("TechnoDerma Medicines"), a clinical-stage biopharmaceutical company which is invested and incubated by Viva BioInnovator (VBI), reported that the Company has completed its Phase 2a clinical trial (NCT06363461) of topical TDM-180935 ointment in patients with Atopic Dermatitis (AD).
- Results show that the treatment was well-tolerated and demonstrated strong efficacy. Only minimal systemic exposure was evident and, thus, will enable future application to large body surface areas often seen in AD. These positive results provide support for continued advancement of the Atopic Dermatitis program.

Mediar Therapeutics Enters into Global Licensing Agreement with Lilly to Advance First-in-Class WISP1 Antibody for the Treatment of Idiopathic Pulmonary Fibrosis (IPF)

- Jan. 10, 2025 -- Mediar Therapeutics, Inc., invested by Viva BioInnovator (VBI), a clinical stage biotechnology company advancing a portfolio of first-in-class therapies designed to halt fibrosis progression, announced a global licensing agreement with Eli Lilly and Company to advance MTX-463 into a Phase 2 clinical trial for idiopathic pulmonary fibrosis (IPF). MTX-463 is a first-in-class human IgG1 antibody designed to neutralize WISP1-mediated fibrotic signaling in several debilitating diseases. The Phase 1 study was recently completed in healthy volunteers and showed MTX-463 to be well-tolerated and engaged WISP1 at all tested doses. The Phase 2 IPF study is designed to evaluate safety, pharmacokinetics, and efficacy in patients. The trial is expected to initiate in the first half of 2025 and will be conducted by Mediar. Following completion of the Phase 2 study, Lilly will have the right to lead all further clinical development and commercialization of the program.

Portfolio Companies' Project Progress

TJ Biopharma Announces NMPA Acceptance of BLA for Felzartamab

- January 10, 2025 – TJ Biopharma ("TJ Bio" or "Company"), invested by Viva BioInnovator (VBI), a fully integrated biotech company in China that develops, manufactures, and commercializes through partnership on innovative biologics for autoimmune diseases, oncology and metabolic diseases, today announced that the Biologics License Application (BLA) submission for felzartamab, an investigational differentiated CD38 antibody, has been accepted for review by China's National Medical Products Administration (NMPA) for the treatment of multiple myeloma (MM). This milestone, following the recent BLA submission for eftansomatropin alfa, demonstrates TJ Bio's proven capability to advance late-stage pipeline products through its full-fledged R&D and manufacturing infrastructure.

Genhouse Bio's New Generation PRMT5 Inhibitor GH56 Clinical Trial Application Approved by NMPA

- January 16, 2025 – Genhouse Bio, invested and incubated by VBI, a biotech company focusing on development of next-generation anti-cancer therapeutics, announced that its clinical trial application for the next generation PRMT5 inhibitor GH56, a Class 1 new drug, has been approved by NMPA. Additionally, on January 24, the clinical trial application for GH56 in the United States was approved by the FDA.

VIVA

Listing Date
B2019.05.09

Price (2025.5.14)
HKD 1.66

52 WK Range
HKD 0.47 – 2.12

Market Cap (2025.5.14.)
HKD 3.539 Billion

Established in 2008, Viva Biotech (01873.HK) provides one-stop services ranging from early-stage Structure-Based Drug R&D to commercial manufacturing to global biopharmaceutical innovators. We offer leading early-stage to late-phase drug discovery expertise by integrating our dedicated team of experts, cutting-edge technology platforms, and state-of-the-art equipment in X-ray crystallization, Cryo-EM, DEL, ASMS, SPR, HDX, AIDD/CADD, and much more. Our business covers all aspects of therapeutic strategies and drug modalities, including small molecules and biologics across the pharma and biotech spectrum. The experienced chemistry team, led by senior medicinal chemists and drug discovery biologists, provides services for drug design, medicinal chemistry (hit to lead and lead optimization), custom synthesis, chemical analysis and purification, kilogram scale-up, peptide synthesis and corresponding bioassays. With our subsidiary, Langhua Pharma, we offer our worldwide pharmaceutical and biotech partners a one-stop integrated CMC (Chemical, Manufacturing, and Control) service from preclinical to commercial manufacturing. Additionally, Viva embedded an equity for service (EFS) model to high potential startups to address unmet medical needs.

As of December 31, 2024, Viva Biotech had cumulatively provided drug R&D and manufacturing services to 2,465 biotech and pharmaceutical clients around the world. We have invested and incubated 93 biotech start-ups in total. In the future, the company will continue to strengthen its technological barriers and improve R&D, production levels, and our service capacity to provide high-quality and diversified services for more drug discovery start-ups, as well as medium and large pharmaceutical enterprises around the world.

Investor & Media Enquiries
Viva Biotech Holdings website: www.vivabiotech.com
For further information, please contact:Tel: +86(0)21-6089 3288
Email: ir@vivabiotech.com